Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancers.

about

Tamoxifen with ovarian function suppression versus tamoxifen alone as an adjuvant treatment for premenopausal breast cancer: a meta-analysis of published randomized controlled trials.

P2860

Q35673773-668F3658-A017-4FC7-BD35-69E4B7B73037

P2860

Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancers.

Item

http://www.wikidata.org/entity/Q41479168

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Genomic predictor of residual ...... eptor-positive breast cancers.

@en

type

Item

label

Genomic predictor of residual ...... eptor-positive breast cancers.

@en

prefLabel

Genomic predictor of residual ...... eptor-positive breast cancers.

@en

P1476

Genomic predictor of residual ...... ceptor-positive breast cancers

@en

P2093

Achim Rody

http://www.w3.org/2001/XMLSchema#string

Lajos Pusztai

http://www.w3.org/2001/XMLSchema#string

Sabrina S Khan

http://www.w3.org/2001/XMLSchema#string

Sven Becker

http://www.w3.org/2001/XMLSchema#string

Uwe Holtrich

http://www.w3.org/2001/XMLSchema#string

Volkmar Müller

http://www.w3.org/2001/XMLSchema#string

W Fraser Symmans

http://www.w3.org/2001/XMLSchema#string

P2860

The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

Supervised risk predictor of breast cancer based on intrinsic subtypes

Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

Data-driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer.

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.

P2888

s10549-015-3277-7

P304

789-797

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-015-3277-7

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

149

http://www.w3.org/2001/XMLSchema#string

P50

Thomas Karn

Christos Hatzis

P577

2015-02-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272074290

http://www.w3.org/2001/XMLSchema#string

P6179

1036419615

http://www.w3.org/2001/XMLSchema#string

P698

25651779

http://www.w3.org/2001/XMLSchema#string

Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancers.

about

P2860

P2860

Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancers.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P6179

P698